Media stories about Cytosorbents Corporation (NASDAQ:CTSO) have been trending somewhat positive on Tuesday, Alpha One reports. The research firm, a subsidiary of Accern, ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytosorbents Corporation earned a media sentiment score of 0.11 on Alpha One’s scale. Alpha One also assigned news headlines about the medical research company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Alpha One’s analysis:
- Cytosorbents Corporation (CTSO) noted a price change of -4.17% and Chiasma, Inc. (CHMA) closes with a move of … – Stocks Gallery (stocksgallery.com)
- Corporate Share Gaps are Down for Wednesday – ALDX, CTSO, TAX, YORW, EMITF, GPIC, PFMT (fxpips.com)
- CytoSorbents Announces Director and Management Open Market Stock Purchases (finance.yahoo.com)
- Cytosorbents Corporation (CTSO) Expected to Post Quarterly Sales of $3.29 Million (americanbankingnews.com)
- Cytosorbents Corp (CTSO)’s Trend Down, Especially After Today’s Yearly Low Hit – WeeklyHub (weeklyhub.com)
A number of research firms have recently commented on CTSO. B. Riley reiterated a “buy” rating and set a $11.25 price target on shares of Cytosorbents Corporation in a report on Wednesday, March 1st. Maxim Group restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents Corporation in a report on Wednesday, March 22nd. HC Wainwright raised their target price on shares of Cytosorbents Corporation from $11.50 to $13.00 and gave the stock a “buy” rating in a report on Monday, March 6th. Finally, Aegis restated a “buy” rating on shares of Cytosorbents Corporation in a report on Tuesday, March 7th. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $12.38.
Shares of Cytosorbents Corporation (NASDAQ:CTSO) traded up 7.333% during midday trading on Tuesday, reaching $4.025. 53,583 shares of the company traded hands. The company’s market capitalization is $113.13 million. Cytosorbents Corporation has a 1-year low of $3.30 and a 1-year high of $6.90. The company has a 50 day moving average price of $4.24 and a 200 day moving average price of $5.07.
Cytosorbents Corporation (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, May 8th. The medical research company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Cytosorbents Corporation had a negative net margin of 108.69% and a negative return on equity of 1,426.21%. The firm had revenue of $3.11 million for the quarter, compared to analyst estimates of $2.99 million. On average, analysts expect that Cytosorbents Corporation will post ($0.28) earnings per share for the current year.
In other news, insider Phillip P. Chan acquired 6,300 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were purchased at an average cost of $4.00 per share, for a total transaction of $25,200.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders purchased 17,500 shares of company stock worth $70,620. 5.60% of the stock is currently owned by insiders.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.